Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus with Docetaxel and Carboplatin in mCRPC
NCT02565901Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Feb 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Washington. Started Feb 2016; status: terminated.
02
Drugs
sirolimus
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02565901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565901.